I-0436650
I-0436650 is an orally active SHP2 inhibitor with an IC50 of 4 nM and a Kd value of 0.3 nM. I-0436650 binds allosterically to the channel between the C-SH2, N-SH2 and PTP catalytic domains, locking the protein in an inactive closed conformation. I-0436650 potently inhibits ERK phosphorylation and suppresses MAPK pathway activity. I-0436650 exhibits antiproliferative activity in EGFR- and RAS-dependent cells. I-0436650 can be used in the research of RAS-driven cancers, EGFR-mutated cancers and RTK-driven cancers.
For research use only. We do not sell to patients.
- CAS No.: 2843690-50-4
- Formula: C22H22ClN9S
- Molecular Weight:479.99
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
SHP2 4 nM (IC50) |
SHP2 0.3 nM (Kd) |
ERK |
p38 MAPK |
EGFR |
Ras |
RTK |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KYSE-520 cell line | IC50 |
13 nM
|
Inhibition of ERK phosphorylation in human EGFR-amplified esophageal squamous cell carcinoma KYSE-520 cells.
Inhibition of ERK phosphorylation in human EGFR-amplified esophageal squamous cell carcinoma KYSE-520 cells.
|
42593923 |
| KYSE-520 cell line | IC50 |
216 nM
|
Antiproliferative activity against human EGFR-amplified esophageal squamous cell carcinoma KYSE-520 cells.
Antiproliferative activity against human EGFR-amplified esophageal squamous cell carcinoma KYSE-520 cells.
|
42593923 |
| NCI-H358 | IC50 |
199 nM
|
Antiproliferative activity against human KRASG12C mutant NCI-H358 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
Antiproliferative activity against human KRASG12C mutant NCI-H358 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
|
42593923 |
| SW837 | IC50 |
367 nM
|
Antiproliferative activity against human KRASG12C mutant SW 837 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
Antiproliferative activity against human KRASG12C mutant SW 837 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
|
42593923 |
| SW1463 | IC50 |
14 nM
|
Antiproliferative activity against human KRASG12C mutant SW 1463 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
Antiproliferative activity against human KRASG12C mutant SW 1463 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
|
42593923 |
| NCI-H1975 | IC50 |
261 nM
|
Antiproliferative activity against human EGFR T790M L858R mutant NCI-H1975 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
Antiproliferative activity against human EGFR T790M L858R mutant NCI-H1975 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
|
42593923 |
| HCC827 | IC50 |
101 nM
|
Antiproliferative activity against human EGFR deletion mutant NCI-HCC827 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
Antiproliferative activity against human EGFR deletion mutant NCI-HCC827 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
|
42593923 |
| NCI-N87 | IC50 |
25 nM
|
Antiproliferative activity against human RTK mutant NCI-N87 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
Antiproliferative activity against human RTK mutant NCI-N87 cells assessed as reduction in cell viability after 6-day incubation using a luminescence-based assay.
|
42593923 |
| NCI-H358 | IC50 |
61 nM
|
Inhibition of ERK phosphorylation in human KRASG12C mutant NCI-H358 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
Inhibition of ERK phosphorylation in human KRASG12C mutant NCI-H358 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
|
42593923 |
| SW837 | IC50 |
58 nM
|
Inhibition of ERK phosphorylation in human KRASG12C mutant SW 837 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
Inhibition of ERK phosphorylation in human KRASG12C mutant SW 837 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
|
42593923 |
| SW1463 | IC50 |
25 nM
|
Inhibition of ERK phosphorylation in human KRASG12C mutant SW 1463 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
Inhibition of ERK phosphorylation in human KRASG12C mutant SW 1463 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
|
42593923 |
| NCI-H1975 | IC50 |
65 nM
|
Inhibition of ERK phosphorylation in human EGFR T790M L858R mutant NCI-H1975 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
Inhibition of ERK phosphorylation in human EGFR T790M L858R mutant NCI-H1975 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
|
42593923 |
| HCC827 | IC50 |
41 nM
|
Inhibition of ERK phosphorylation in human EGFR deletion mutant NCI-HCC827 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
Inhibition of ERK phosphorylation in human EGFR deletion mutant NCI-HCC827 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
|
42593923 |
| NCI-N87 | IC50 |
48 nM
|
Inhibition of ERK phosphorylation in human RTK mutant NCI-N87 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
Inhibition of ERK phosphorylation in human RTK mutant NCI-N87 cells after 6-hour incubation quantified using an electrochemiluminescence assay.
|
42593923 |
In Vitro
I-0436650 potently and selectively inhibits full-length human wild-type and mutant SHP2 proteins, with no activity against the isolated SHP2-PTP catalytic domain or human SHP1, confirming its allosteric mechanism of action[1].
I-0436650 tightly binds to human SHP2 with low nanomolar affinity and a very slow dissociation rate, resulting in an extended residence time on the target[1].
I-0436650 inhibits MAPK pathway signaling (measured by pERK) and proliferation in KYSE-520 cells with low nanomolar and submicromolar potency, respectively[1].
I-0436650 (1 pM-10 mM; 6 days) exhibits broad antiproliferative activity across genetically diverse KRAS-, EGFR-, and RTK-driven human cancer cell lines, with varying potency reflecting underlying oncogenic drivers[1].
I-0436650 (1 pM-10 mM; 6 hours) effectively inhibits MAPK pathway signaling via suppression of ERK phosphorylation in KRAS-, EGFR-, and RTK-driven human cancer cell lines after 6 hours of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human KRASG12C mutant NCI-H358, SW 837, SW 1463 cells; human EGFR T790M L858R mutant NCI-H1975 cells; human EGFR deletion mutant NCI-HCC827 cells; human RTK mutant NCI-N87 cells
-
Concentration:1 pM-10 mM
-
Incubation Time:6 days
-
Result:Induced dose-dependent reduction in cell viability in NCI-H358 cells with an IC50 of 199 nM.
Induced dose-dependent reduction in cell viability in SW 837 cells with an IC50 of 367 nM.
Induced dose-dependent reduction in cell viability in SW 1463 cells with an IC50 of 14 nM.
Induced dose-dependent reduction in cell viability in NCI-H1975 cells with an IC50 of 261 nM.
Induced dose-dependent reduction in cell viability in NCI-HCC827 cells with an IC50 of 101 nM.
Induced dose-dependent reduction in cell viability in NCI-N87 cells with an IC50 of 25 nM.
Parmacokinetics
| Species | Dose | Route | T1/2 | AUC | CLplasma | Vdss | Tmax | Cmax | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1 mg/kg | i.v. | 4.2 h | 36.2 μM·h | 1.0 mL/min/kg | 0.3 L/kg | / | / | / |
| Mice[1] | 3 mg/kg | p.o. | / | 43.0 μM·h | / | / | 1 h | 5.4 μM | 40 % |
| Rat[1] | 0.45 mg/kg | i.v. | 3.7 h | 6.5 μM·h | 2.4 mL/min/kg | 0.7 L/kg | / | / | / |
| Rat[1] | 0.9 mg/kg | p.o. | / | 9.4 μM·h | / | / | 1.5 h | 2.1 μM | 78 % |
| Dog[1] | 0.1 mg/kg | i.v. | 13.8 h | 0.8 μM·h | 5.1 mL/min/kg | 2.6 L/kg | / | / | / |
| Dog[1] | 0.25 mg/kg | p.o. | / | 0.9 μM·h | / | / | 3 h | 0.06 μM | 49 % |
In Vivo
I-0436650 (20 mg/kg; p.o.; once daily; 21 days), when combined with Osimertinib (HY-15772), restores antitumor efficacy in osimertinib-resistant NCI-H1975 xenografts, achieving 65% tumor growth inhibition relative to vehicle[1].
I-0436650 (20 mg/kg; p.o.; once daily) potentiates the antitumor activity of adagrasib in KRASG12C-mutant NCI-H2122 xenografts, achieving 86% tumor growth inhibition relative to vehicle on day 21 and delaying tumor relapse[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD1 nude mice (female)[1]
-
Dosage:20 mg/kg; 40 mg/kg; 80 mg/kg
-
Administration:p.o.; once daily; 21 days; p.o.; twice daily; 21 days
-
Result:Reduced tumor volumes to 42.6% of vehicle controls with 20 mg/kg QD dose on day 21.
Reduced tumor volumes to 18.6% of vehicle controls with 20 mg/kg BID dose on day 21.
Reduced tumor volumes to 29.1% of vehicle controls with 40 mg/kg QD dose on day 21.
Reduced tumor volumes to 11.7% of vehicle controls with 80 mg/kg QD dose on day 21.
Achieved 88.3% tumor growth inhibition with 80 mg/kg once daily relative to vehicle.
Reduced pERK-positive tumor cell density relative to vehicle controls.
Reduced Ki67-positive proliferating cell density relative to vehicle controls.
Caused no significant body weight changes with all dosing regimens.
-
Animal Model:CD1 nude mice (female)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; once daily; 21 days
-
Result:Reduced tumor volumes to 35% of vehicle controls when combined with Osimertinib 5 mg/kg QD on day 21.
Achieved 65% tumor growth inhibition relative to vehicle when combined with Osimertinib.
Restored antitumor activity in Osimertinib-resistant model.
Caused no increased toxicity relative to single agents.
-
Animal Model:CD1 nude mice[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; once daily
-
Result:Reduced tumor volumes to 52% of vehicle controls with monotherapy on day 21.
Reduced tumor volumes to 14% of vehicle controls when combined with adagrasib 50 mg/kg QD on day 21.
Achieved 86% tumor growth inhibition relative to vehicle on day 21 when combined with adagrasib.
Enhanced initial tumor growth inhibition compared to adagrasib monotherapy.
Delayed tumor relapse compared to adagrasib monotherapy when monitored up to 40 days.
Chemical Information
-
CAS No. 2843690-50-4
-
Molecular Weight 479.99
-
Formula C22H22ClN9S
-
SMILES
ClC1=C(N2C=CC=N2)N=CC=C1SC3=NC=C(N4CCC5(CC4)[C@@H](C6=CC=NN6C5)N)N=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)